In preterm participants, the weight at 36-weeks' postmenstrual age and at discharge was also collected to include them in the EUGR or AEUG groups according to the weight percentile charts for age, sex and GA established by Carrascosa et al
However, these have a very limited effect on the symptoms of CTS, because these medications do not relieve the pressure on the Median Nerve
In subcutaneous research protocols, doses of 1 to 4 mg per application are typically employed, with a frequency of 2 to 3 times per week
The evolving medication landscape underscores the importance of individualized treatment planning, integrating both pharmacological and behavioral interventions to support long-term recovery across substance categories
This can be beneficial for treating anti-inflammatory illness, as HA improves both permeability and biocompatibility [355]